Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis
Marianna Fontana(Johnson & Johnson (United States)), James Moon(Virginia Mason Medical Center), Sanjay M Banypersad(University College Hospital at Westmoreland Street), Peter Kellman(National Institutes of Health), Helen J. Lachmann(Royal Free London NHS Foundation Trust), Silvia Pica(National Institutes of Health), Philip N. Hawkins(The Royal Free Hospital), Thomas A. Treibel(National Institutes of Health), Charlotte Manisty(National Institutes of Health), Stefania Rosmini(National Institutes of Health), Julian D. Gillmore(Alnylam Pharmaceuticals (United States)), Heerajnarain Bulluck(National Institutes of Health), Carol Whelan(Boston University), Shameem Mamhood(National Institutes of Health), Ashutosh Wechalekar(Boston University), William Barcella(National Institutes of Health), Chiara Bucciarelli‐Ducci(University Hospitals Bristol NHS Foundation Trust), Patricia Réant(National Institutes of Health), Amna Abdel‐Gadir(National Institutes of Health), Ketna Patel(National Institutes of Health), Eric B. Schelbert(National Institutes of Health), Viviana Maestrini(National Institutes of Health), Rabya Sayed(National Institutes of Health), Anna S Herrey(National Institutes of Health)
Cited by 610
Related Papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k
2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease
|European Heart Journal|2020|1.8k
NALP3 Forms an IL-1β-Processing Inflammasome with Increased Activity in Muckle-Wells Autoinflammatory Disorder
|Immunity|2004|1.7k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k